Dr Hope Rugo speaks to ecancer about the subgroup analyses of PALOMA-3 trial, the results of which were presented at the virtual EBCC-12 conference this year.
Dr Rugo starts with explaining the objectives and the end-points that were evaluated in this trial. She then explains the predictors of efficacy in patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR /HER2– ABC).
Dr Rugo whilst explaining the results says that this trial showed palbociclib showed a good prognosis value when treated in combination with fulvestrant in this type of. breast cancer. In the end, talks about how these results can have an impact on the treatment of HR /HER2- breast cancer.